BIOMIGA

Migraine is a common neurological disorder and a major source of disability. Though curable in principle, migraine generally improves poorly with available treatments, due to their limited efficacy and scarce tolerability. In 2018, monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) receptor have been approved. These mABs are the first specific preventive treatment for migraine ever developed. They are highly effective in a subgroup of patients, well tolerated, but costly. The main objective of this project is the identification of predictive biomarkers of response to CGRP-targeted mAbs in patients with migraine. In this project, we used a hypothesis-driven, multidisciplinary approach that combines fundamental research in a validated animal model of migraine with a variegated and integrated 'omics' approach on a carefully characterized population of migraine sufferers. In the shared folder it is possible to find all the anonymised raw data regarding: - clinical, psychological and disability measures of the patients before and after the use of erenumab - MRI scan (fRMI and T13D and perfusion map) - epigenetics analysis: level of methylation of the cpg island of relevant gene associated with migraine and CGRP - biochemical evaluation of circulating inflammatory peptide and gene expression level - genetic profiling